The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: An updated systematic review

Gynecological Endocrinology

Volumn 24, Issue 10, 2008, Pages 590-600

  Jing, Zhang ^a,b   Liang Zhi, Xu ^a,b   Tai Xiang, Wu ^b   Ying, Tang ^a   Yu Jian, Jia ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cyproterone acetate; Meta analysis; Metformin; Polycystic ovary syndrome; Systematic review; Therapy

Indexed keywords

DIANE; INSULIN; METFORMIN; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; LIPID METABOLISM; META ANALYSIS; MONOTHERAPY; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ALGORITHMS; ANDROGEN ANTAGONISTS; CYPROTERONE ACETATE; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME;

EID: 56549114144     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802288242     Document Type: Article

References (47)

1. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathies associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899.
2. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular genetic basis of functional hyperandrogenism and polycystic ovary syndrome. Endocr Rev 2005;26:251-282.
3. Gambineri A, Pasquali R. Insulin resistance, obesity and metabolic syndrome in polycystic ovary syndrome. Endocrinol Nutr 2006; 53(Suppl 1): 49-55.
4. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006;166:2081-2086.
5. Dunaif A. Insulin resistance and the polycystic ovary syndrome mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
6. Ehrmann DA, Cavaghan MK, Barnes RB, Imperial J, Rosenfield RL. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146.
7. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
8. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673-683.
9. Lo JC, Feigenbaum SL, Escobar GJ, Yang J, Crites YM, Ferrara A. Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome a population based study. Diabetes Care 2006;29:1915-1917.
10. Rajkhowa M, Neary RH, Kumpatla P, Garne FL, Jones PW, Obhrai MS, Clayton RN. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389-3394.
11. Berneis K, Rizzo M, Lazzaroni V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:186-189.
12. Talbott I, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Englerg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998;51:415-422.
13. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-613.
14. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1357-1363.
15. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-1935.
16. Ehrmann DA, Lljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-52.
17. Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997;82:3074-3077.
18. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161-3168.
19. Tavior AE. Insulin lowering medications in polycystic ovary syndrome. Obstet Gynecol Cim North Am 2000;27:583-595.
20. Korytkowski M, Mokan M, Horwitz M, Berga S. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:3327-3334.
21. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30:471-478.
22. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez-Bermejo E, Lasuncion MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2453-2461.
23. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148-156.
24. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4116-4123.
25. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-579.
26. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-146.
27. Carlsen SM, Rossvoll O, Bjerve KS, Folling I. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 1996;239:227-233.
28. Marquie G. Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits. Atherosclerosis 1983;47:7-17.
29. Lord J, Flight I, Norman R. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiroinositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003: CD003053.
30. Diamanti-Kandarakis E, Baillargeon J, Iuorno M, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927-1932.
31. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569-574.
32. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005;152:269-275.
33. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524-530.
34. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-654.
35. Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007;22:1200-1209.
36. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical studies. BMJ 2001;323:42-46.
37. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in healthcare: meta-analysis in context. London: BMJ Books; 2001. pp 285-312.
38. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. 1st ed. Chichester UK: John Wiley and Sons; 2000.
39. Hatala R, Keitz S, Wyer P, Guyatt G, on behalf of the Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 2005;172:661-665.
40. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4649-4654.
41. Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2005;118:209-213.
42. Jin LN, Yu Q, Ma LK. Clinical analysis of 48 cases polycystic ovary syndrome. Chin J Postgrad Med 2006;29(7):10-15.
43. Teng YQ, Zheng JH, Han XY. [Evaluation of clinical efficacy of metformin in treating polycystic ovary syndrome]. J Harbin Med Univ 2007;41:405-406.
44. Liu JX, Dang JM, Wu YZ, Zheng N, Wu XK. The effect of combination therapy with metformin and combined cyproterone acetate/ethinyloestradiol on PCOS patients. J Med Postgrad 2006;19:530-533.
45. Lv LQ, Liu Y, Sun YY, Tan K. Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. J Huazhong Univ Sci Technol (Med Sci) 2005;25:194-197.
46. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002;17:1729-1737.
47. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007;(1):CD005552.